Restoring T-helper 17 cell/regulatory T-cell balance and decreasing disease activity by rapamycin and all-trans retinoic acid in patients with systemic lupus erythematosus
Restricted accessResearch articleFirst published online October, 2019
Restoring T-helper 17 cell/regulatory T-cell balance and decreasing disease activity by rapamycin and all-trans retinoic acid in patients with systemic lupus erythematosus
This study aimed to investigate the effect of rapamycin (RAPA) alone or in combination with all-trans retinoic acid (ATRA) on the T-helper 17 (Th17) cell/regulatory T-cell (Treg) balance in patients with systemic lupus erythematosus (SLE) and to evaluate the clinical efficacy.
Methods
Seventy patients with SLE were enrolled. They were randomly and equally divided into RAPA and RAPA + ATRA groups. The number of Th17 and Treg cells was measured by flow cytometry before and after treatment for 6, 12 and 24 weeks. The SLE Disease Activity Index (SLEDAI) score and the prednisone dose before and after treatment were used to evaluate the efficacy between the two groups.
Results
In both groups, at different time points after treatment, the number of Th17 cells (p = 0.003) and Th17/Treg ratio (p = 0.044) reduced, while the number of Treg cells (p = 0.574) tended to increase. The SLEDAI score and the dose of prednisone decreased significantly (p < 0.001). There was no significant difference in the number of Th17 cells (p = 0.089), Treg cells (p = 0.059), Th17/Treg ratio (p = 0.580), SLEDAI score (p = 0.127) and the dose of prednisone (p = 0.329) between the two groups.
Conclusion
Disease activity in SLE patients reduced with RAPA alone or in conjunction with ATRA, reducing glucocorticoid requirement. One of its mechanisms of action may be regulating the Th17/Treg cell balance, which provides a new model for the pathogenesis and potential treatment of SLE.
MoultonVRTsokosGC. T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J Clin Invest2015; 125: 2220–2227.
2.
MoultonVRSuarez-FueyoAMeidanELiHMizuiMTsokosGC. Pathogenesis of human systemic lupus erythematosus: a cellular perspective. Trends Mol Med2017; 23: 615–635.
3.
KatsuyamaTTsokosGCMoultonVR. Aberrant T cell signaling and subsets in systemic lupus erythematosus. Front Immunol2018; 9: 1088–1088.
4.
MaJYuJTaoXCaiLWangJZhengSG. The imbalance between regulatory and IL-17 secreting CD4+T cells in lupus patients. Clin Rheumatol2010; 29: 1251–1258.
5.
LaiZ-WBorsukRShadakshariA, et al.Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus. J Immunol2013; 191: 2236–2246.
6.
WangXWangWXuJWuSLeQ. All-trans retinoid acid promotes allogeneic corneal graft survival in mice by regulating Treg–Th17 balance in the presence of TGF-β. BMC Immunol2015; 16: 17–17.
7.
JhunjhunwalaSChenLCNicholsEEThomsonAWRaimondiGLittleSR. All-trans retinoic acid and rapamycin synergize with transforming growth factor-beta1 to induce regulatory T cells but confer different migratory capacities. J Leukoc Biol2013; 94: 981–989.
8.
ScottaCEspositoMFazekasovaH, et al.Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4(+)CD25(+)FOXP3(+) T regulatory cell subpopulations. Haematologica2013; 98: 1291–1299.
9.
FernandezDBonillaEMirzaNNilandBPerlA. Rapamycin reduces disease activity and normalizes T cell activation–induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum2006; 54: 2983–2988.
10.
LaiZWRyanKThomasW, et al.Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, Phase 1/2 trial. Lancet2018; 391: 1186–1196.
11.
YapDYMaMKTangCSChanTM. Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience. Nephrol (Carlton)2012; 17: 676–680.
12.
KinoshitaKKishimotoKShimazuH, et al.Successful treatment with retinoids in patients with lupus nephritis. Am J Kidney Dis2010; 55: 344–347.
13.
HochergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
LittmanDRRudenskyAY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell2010; 140: 845–858.
16.
AlunnoABartoloniEBistoniO, et al.Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. Clin Dev Immunol2012; 2012: 823085–823085.
17.
YangJYangXZouHChuYLiM. Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus. Rheumatol (Oxford)2011; 50(8): 1366–1372.
18.
MinSSNaeunLInsooK. Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Curr Opin Rheumatol2011; 23: 444–448.
19.
MizuiMTsokosGC. Targeting regulatory T cells to treat patients with systemic lupus erythematosus. Front Immunol2018; 9: 786–786.
20.
HuangNPerlA. Metabolism as a target for modulation in autoimmune diseases. Trends Immunol2018; 39: 562–576.
21.
PerlAHanczkoRLaiZW, et al.Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin. Metabolomics2015; 11: 1157–1174.
22.
PerlA. Review: metabolic control of immune system activation in rheumatic diseases. Arthritis Rheum2017; 69: 2259–2270.
23.
KurebayashiYNagaiSIkejiriA, et al.PI3K–Akt–mTORC1–S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORγ. Cell Rep2012; 1: 360–373.
24.
KatoHPerlA. Blockade of Treg cell differentiation and function by the interleukin-21–mechanistic target of rapamycin axis via suppression of autophagy in patients with systemic lupus erythematosus. Arthritis Rheum2018; 70: 427–438.
25.
QiYZhouXChengF, et al.Increased autophagy is cytoprotective against podocyte injury induced by antibody and interferon-α in lupus nephritis. Ann Rheum Dis2018; 77: 1799–1809.
26.
CassaniBVillablancaEJDe CalistoJWangSMoraJR. Vitamin A and immune regulation: role of retinoic acid in gut-associated dendritic cell education, immune protection and tolerance. Mol Aspects Med2012; 33: 63–76.
27.
WeiSYoshidaNFinnG, et al.Pin1-targeted therapy for systemic lupus erythematosus. Arthritis Rheum2016; 68: 2503–2513.
28.
Perez de LemaGLucio-CazanaFJMolinaA, et al.Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease. Kidney Int2004; 66: 1018–1028.
29.
LuLLanQLiZ, et al.Critical role of all-trans retinoic acid in stabilizing human natural regulatory T cells under inflammatory conditions. Proc Natl Acad Sci U S A2014; 111: E3432–E3440.
30.
GolovinaTNMikheevaTBruskoTMBlazarBRBluestoneJARileyJL. Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One2011; 6: e15868–e15868.
31.
BeermannJLThieslerCTDringenbergU, et al.Migratory properties of ex vivo expanded regulatory T cells: influence of all-trans retinoic acid and rapamycin. Transpl Immunol2017; 45: 29–34.
32.
SchmidtAErikssonMShangMMWeydHTegnérJ. Comparative analysis of protocols to induce human CD4+Foxp3+ regulatory T cells by combinations of IL-2,TGF-beta, retinoic acid, rapamycin and butyrate. PLoS One2016; 11: e0148474–e0148474.
33.
Yildirim-TorunerCDiamondB. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol2011; 127: 303–312.
